Positive Epilepsy Treatment Announced By This Healthcare Company

Longboard Pharmaceuticals Announces Encouraging Data from PACIFIC Study on Bexicaserin (LP352).

Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

Longboard Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced positive topline data from the PACIFIC study, a Phase 1b/2a clinical trial for Bexicaserin (LP352) in participants with Deve…